main content start
Steglatro (ertugliflozin) is a type 2 diabetes oral medication in the SGLT-2 inhibitor class of drugs. It blocks glucose from being reabsorbed by the kidneys. Excess glucose is released in the urine.
- Steglatro is used to improve blood glucose management in adults with type 2 diabetes.
- It is not for treating type 1 diabetes.
- Steglatro is usually taken once per day in the morning. It may be taken with or without food.
- The usual initial dose of Steglatro is 5 mg taken by mouth once a day in the morning. The dose may increase to 15 mg by mouth once a day for patients requiring additional glycemic management who are tolerating it well.
- Common side effects may include increased urinary frequency, dizziness and genital yeast infections.
Steglatro Specs
Key specification
Generic Name
Ertugliflozin
Drug Class
SGLT-2 inhibitors
General Information
Product Name
Steglatro
Product Type
Oral Medications
Brand
Merck
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
